Because our previously published results had revealed that increased endolysosomal cholesterol levels act as an effective antiviral barrier for enveloped viruses, including influenza viruses [12–14,23], we also tested the impact of a post-infection treatment with U18666A, a small molecule inhibitor of the endolysosomal cholesterol transporter NPC1 [17] on SARS-CoV-2 infection. The gene discussed is NPC1; the disease is infection.